Partial versus radical nephrectomy for complex renal mass: multicenter comparative analysis of functional outcomes (Rosula collaborative group).


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
Aug 2023
Historique:
medline: 3 8 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

Utility of partial nephrectomy (PN) for complex renal mass (CRM) is controversial. We determined the impact of surgical modality on postoperative renal functional outcomes for CRM. We retrospectively analyzed a multicenter registry (ROSULA). CRM was defined as RENAL Score 10-12. The cohort was divided into PN and radical nephrectomy (RN) for analyses. Primary outcome was development of de-novo estimated glomerular filtration rate (eGFR)<45 mL/min/1.73 m We analyzed 969 patients (RN=429/PN=540; median follow-up 24.0 months). RN patients had lower BMI (P<0.001) and larger tumor size (P<0.001). Overall postoperative complication rate was higher for PN (P<0.001), but there was no difference in major complications (Clavien III-IV; P=0.702). MVA demonstrated age (HR=1.05, P<0.001), tumor-size (HR=1.05, P=0.046), RN (HR=2.57, P<0.001), and BMI (HR=1.04, P=0.001) to be associated with risk for de-novo eGFR<60 mL/min/1.73 m PN provides functional benefit in selected patients with CRM without significant increase in major complications compared to RN, and should be considered when technically feasible.

Sections du résumé

BACKGROUND BACKGROUND
Utility of partial nephrectomy (PN) for complex renal mass (CRM) is controversial. We determined the impact of surgical modality on postoperative renal functional outcomes for CRM.
METHODS METHODS
We retrospectively analyzed a multicenter registry (ROSULA). CRM was defined as RENAL Score 10-12. The cohort was divided into PN and radical nephrectomy (RN) for analyses. Primary outcome was development of de-novo estimated glomerular filtration rate (eGFR)<45 mL/min/1.73 m
RESULTS RESULTS
We analyzed 969 patients (RN=429/PN=540; median follow-up 24.0 months). RN patients had lower BMI (P<0.001) and larger tumor size (P<0.001). Overall postoperative complication rate was higher for PN (P<0.001), but there was no difference in major complications (Clavien III-IV; P=0.702). MVA demonstrated age (HR=1.05, P<0.001), tumor-size (HR=1.05, P=0.046), RN (HR=2.57, P<0.001), and BMI (HR=1.04, P=0.001) to be associated with risk for de-novo eGFR<60 mL/min/1.73 m
CONCLUSIONS CONCLUSIONS
PN provides functional benefit in selected patients with CRM without significant increase in major complications compared to RN, and should be considered when technically feasible.

Identifiants

pubmed: 37530659
pii: S2724-6051.23.05123-6
doi: 10.23736/S2724-6051.23.05123-6
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

425-433

Auteurs

Clara Cerrato (C)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.

Margaret F Meagher (MF)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Riccardo Autorino (R)

Division of Urology, VCU Health System, Richmond, VA, USA.

Giuseppe Simone (G)

Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Bo Yang (B)

Department of Urology, Changhai Hospital, Shanghai, China.

Robert G Uzzo (RG)

Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Alexander Kutikov (A)

Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Francesco Porpiglia (F)

Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.

Umberto Capitanio (U)

Division of Experimental Oncology, Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Francesco Montorsi (F)

Division of Experimental Oncology, Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.

James Porter (J)

Swedish Urology Group, Seattle, WA, USA.

Alp T Beksac (AT)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Dhruv Puri (D)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Mimi Nguyen (M)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Luke Wang (L)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Kevin Hakimi (K)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Sohail Dhanji (S)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Franklin Liu (F)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Maria A Cerruto (MA)

Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.

Savio D Pandolfo (SD)

Division of Urology, VCU Health System, Richmond, VA, USA.

Andrea Minervini (A)

Department of Urology, University of Florence, Florence, Italy.

Clayton Lau (C)

Division of Urology and Urologic Oncology, City of Hope Medical Center, Duarte, CA, USA.

Aron Monish (A)

Institute of Urology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Daniel Eun (D)

Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

Alexandre Mottrie (A)

Department of Urology, OLV Hospital, Aalst, Belgium.

Carmen Mir (C)

Department of Urology, Hospital Universitario de la Ribera, Valencia, Spain.

Chandru Sundaram (C)

Department of Urology, Indiana University Health, Indianapolis, IN, USA.

Alessandro Antonelli (A)

Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.

Jihad Kaouk (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Ithaar H Derweesh (IH)

Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA - iderweesh@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH